Novartis AG
NVS
$147.85
$4.913.44%
NYSE
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -12.48% | -14.51% | 23.17% | 24.49% | 34.15% |
| Total Depreciation and Amortization | 3.39% | 0.86% | 8.35% | 3.94% | -0.52% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -56.94% | 106.88% | -71.20% | 130.91% | 18.73% |
| Change in Net Operating Assets | 47.43% | -794.90% | 29.13% | 426.00% | 14.02% |
| Cash from Operations | 0.85% | -46.01% | 4.53% | 36.70% | 60.93% |
| Capital Expenditure | -36.22% | -9.14% | -10.28% | -27.31% | -11.89% |
| Sale of Property, Plant, and Equipment | -50.00% | -97.87% | 0.00% | -97.30% | 900.00% |
| Cash Acquisitions | -- | -172.07% | -60.34% | 49.47% | -- |
| Divestitures | 50.00% | -105.49% | -1,014.29% | 57.69% | 89.47% |
| Other Investing Activities | 12.11% | 85.49% | -11,566.67% | -171.04% | 246.70% |
| Cash from Investing | -3,656.36% | 30.63% | -129.95% | 30.06% | 136.71% |
| Total Debt Issued | 1,998.02% | 21,458.33% | -96.32% | -72.06% | -54.43% |
| Total Debt Repaid | 91.47% | -2,147.56% | 44.31% | 69.71% | -1,510.45% |
| Issuance of Common Stock | -- | -- | -60.00% | -20.00% | -- |
| Repurchase of Common Stock | 30.96% | 46.42% | 19.34% | -67.95% | -147.13% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -16.20% | -- | -- | -2.81% | -2.42% |
| Other Financing Activities | 239.13% | 3.13% | 151.16% | -760.00% | 309.09% |
| Cash from Financing | 141.87% | 156.17% | -630.10% | -62.91% | -65.53% |
| Foreign Exchange rate Adjustments | -142.78% | 111.46% | -112.50% | 1,223.53% | 242.86% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -3.76% | 187.40% | -49.18% | 73.82% | -11.95% |